Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539164 | 1.00 | GRIN1 (0.36) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL15043702 | 1.00 | GRIN1 (0.36) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL18707309 | 0.94 | SIRT2 (0.33) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL573648 | 0.86 | SIRT2 (0.40) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL3531548 | 0.83 | GRIN1 (0.41) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL13017847 | 0.82 | SIRT2 (0.38) | CETP | |
| SCHEMBL28747959 | 0.81 | GRIN1 (0.40) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL6570244 | 0.80 | SIRT2 (0.44) | CETP | |
| SCHEMBL15042435 | 0.79 | LMNA (0.34) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL10178235 | 0.79 | LMNA (0.34) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | GRIN1 606/4885GRIN2A 1492/4885GRIN2D 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.